Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday

Tempest Therapeutics (NASDAQ:TPST) is projected to announce its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.62) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Tempest Therapeutics Price Performance

Shares of TPST opened at $1.75 on Wednesday. Tempest Therapeutics has a 1-year low of $1.72 and a 1-year high of $12.23. The stock has a market cap of $8.63 million, a price-to-earnings ratio of -0.17 and a beta of -2.42. The firm has a 50 day simple moving average of $2.42 and a 200-day simple moving average of $5.46.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tempest Therapeutics currently has an average rating of “Reduce” and an average target price of $12.50.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. raised its holdings in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the quarter. Vanguard Group Inc. owned approximately 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.